Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cysticlean
- Development stage
- Unknown
- Lead developer
- Vita Green Europa
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Cysticlean is a botanical product and Class IIa medical device developed by Vita Green Europa S.A., primarily indicated for the prevention and treatment of urinary tract infections (UTIs) and cystitis. Its active component is a concentrated dry extract of the American cranberry (*Vaccinium macrocarpon*), standardized to provide a high dose of 240 mg of proanthocyanidins (PAC) per capsule. The mechanism of action is based on the anti-adhesion properties of PACs, which interfere with the ability of *Escherichia coli* bacteria to adhere to the epithelial lining of the bladder and urinary tract, thereby preventing colonization and infection. Marketed in Europe since 2007, Cysticlean has been studied in Phase 4 clinical trials to evaluate its efficacy as a non-antibiotic alternative for uncomplicated cystitis in women.
- Brand names
- CysticleanCysticlean 240mg PACCysticlean240mg PACCysticlean-240mg PAC
- Other names
- American cranberry extractVaccinium macrocarpon extract
02
Targets
PapG (PapG adhesin)FimH (Type 1 fimbrial adhesin)Uropathogenic Escherichia coli cell surface and biofilm matrix components
Beyond the preview
Go deeper on Cysticlean.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cysticlean.